🇺🇸 EyePoint Pharmaceuticals, Inc.
Forum topic · EYPT · Company page: financials, ownership and filings
Join the discussion on EyePoint Pharmaceuticals, Inc.
Loading…
Results announced on 12 November 2026
EyePoint Pharmaceuticals, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $760,000 (down 22% from a year earlier) and a net loss of $96 million.
Reported to the SEC: Restructuring
EyePoint Pharmaceuticals, Inc. reported on 19 October 2026 (SEC Form 8-K):
• Restructuring: A plan to exit or dispose of activities, usually with job cuts.
This is the SEC's classification of the filing; the filing itself has the details.
Results announced on 19 October 2026
EyePoint Pharmaceuticals, Inc. announced results on 19 October 2026 (SEC Form 8-K, item 2.02).
For the quarter ended 30 September 2026: revenue of $760,000 (down 22% from a year earlier) and a net loss of $96 million.
Layoff notice: a number of people that is not stated
A restructuring plan at EyePoint Pharmaceuticals, Inc. was announced on 17 October 2026: a number of people that is not stated affected.
Source: SEC filing (8-K Item 2.05).
Mutual funds: 147 funds hold $339 million
147 mutual funds in 1 country hold shares of EyePoint Pharmaceuticals, Inc. worth $339 million, about 22.2% of the company (funds' newest reports, up to 31 July 2026).
Since their previous reports 78 funds added shares and 37 sold; on balance they bought $15 million. Share splits are not counted as trading.
Source: Automatic updates: SEC filings, regulators' notices and fund reports held on this site. Posts marked 🤖 are written automatically from official data and state no opinion. Member comments are their authors' views, shown after an editor's review; they are not investment advice.